By Jen Burstedt, Marketing and Communications
Professor Keith Wesnes, Practice Leader at Bracket will be speaking at two sessions during Global Technology Community’s 7th Annual Neurodegenerative Conditions Research & Development meeting, occurring September 9 – 10th, 2013 in Boston, MA.
The sessions are below and include Prof. Wesnes’ role, as either a moderator or presenter, along with the colleagues with whom he’s presenting.
A complete agenda for the event can be found at this link.
September 10th, 8:00 am Eastern
“Novel Therapeutic Targets and Approaches in Parkinson’s Disease”
Professor Wesnes will moderate multiple sessions, including:
• Targeted Drug Delivery to the Midbrain for Parkinson’s Disease Treatment Richard Grondin, Assistant Professor, Anatomy and Neurobiology, University of Kentucky College of Medicine
• LRRK2 as a Therapeutic Target for Parkinson’s Disease: Challenges and Recent Progress
Warren Hirst, Associate Research Fellow & Group Leader, Neurodegeneration & Neurologic Diseases, Pfizer
• IRX4204, a Selective Nurr1 Transactivator, as a Disease-Modifying Agent in the Attenuation of Parkinson’s Disease Dopaminergic Degeneration
Giulio Maria Pasinetti, Saunders Family Professor in Neurology, Mount Sinai School of Medicine
• Jonathan Brotchie, Senior Scientist, Toronto Western Research Institute
September 10th, 11:05 pm Eastern
Joint Session with 6th CNS Partnering and Deal Making Conference: Recent Developments in Neuroscience Research
Moderator: Santosh D’Mello, Professor, Molecular & Cell Biology, University of Texas, Dallas “Detecting Cognition Enhancement in Clinical Trials: Exciting New Opportunities for Cognitive Test Systems That Work”
Current focus on substances to improve human cognition function mainly concerns ADHD, schizophrenia and pathological cognitive ageing including the dementias. Sporadic recent interest has also been directed at depression, head injury, stroke, Parkinson’s disease and recovery from major surgery including cardiac bypass. However all CNS disorders and many general diseases are associated with cognitive impairment, and effective treatments can produce collateral reductions to such impairment. Despite the widespread and radical technological advances which characterize modern drug development, the bulk of tests currently used to assess changes in cognitive function in clinical trials are pencil and paper based neuropsychological tests; many developed in the first half of the last century. These tests can be lengthy to perform, have limited or no alternate forms for repeated administration and mostly require specialist administration and scoring. Automated tests of attention date back over 140 years, and computerized cognitive tests have been used in most areas of clinical research since the 1980s. Thus today such methodology can hardly be considered radical or even innovative. This presenter has used automated tests for 4 decades, and will seek to extol the virtues of automation and expose the shortcomings of traditional neuropsychological tests. Data obtained by both methodologies will be reviewed from large programs such as ADNI and major clinical trials. The FDA has recently aroused much interest by publically stating that treatments for the earliest stages of Alzheimer’s could be approved by cognitive testing alone. Overall, huge opportunities exist for the development of compounds to treat cognitive impairment in a wide range of conditions, and success will be heavily influenced by the quality of the instruments employed.
1. Appreciate the widespread opportunities for assessing cognitive function in drug development
2. Understand the essential requirements of cognitive tests for clinical trials
3. Get up to speed with the latest direction for treating Alzheimer’s at the preclinical stage
4. Increase the clinical and marketing potential of novel therapies